Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MDGL - US5588681057 - Common Stock

503.68 USD
+2 (+0.4%)
Last: 1/20/2026, 3:16:56 PM
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of MDGL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, MDGL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MDGL has reported negative net income.
  • In the past year MDGL has reported a negative cash flow from operations.
  • MDGL had negative earnings in each of the past 5 years.
  • MDGL had a negative operating cash flow in each of the past 5 years.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • MDGL's Return On Assets of -21.22% is fine compared to the rest of the industry. MDGL outperforms 74.86% of its industry peers.
  • Looking at the Return On Equity, with a value of -46.21%, MDGL is in the better half of the industry, outperforming 68.19% of the companies in the same industry.
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • MDGL has a better Gross Margin (95.25%) than 95.24% of its industry peers.
  • The Profit Margin and Operating Margin are not available for MDGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

  • MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDGL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MDGL has more shares outstanding
  • MDGL has a better debt/assets ratio than last year.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 7.83 indicates that MDGL is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.83, MDGL is doing good in the industry, outperforming 78.67% of the companies in the same industry.
  • A Debt/Equity ratio of 0.54 indicates that MDGL is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.54, MDGL is doing worse than 70.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z 7.83
ROIC/WACCN/A
WACC8.83%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 3.44 indicates that MDGL has no problem at all paying its short term obligations.
  • MDGL has a Current ratio of 3.44. This is comparable to the rest of the industry: MDGL outperforms 41.33% of its industry peers.
  • A Quick Ratio of 3.26 indicates that MDGL has no problem at all paying its short term obligations.
  • MDGL has a Quick ratio of 3.26. This is comparable to the rest of the industry: MDGL outperforms 41.33% of its industry peers.
Industry RankSector Rank
Current Ratio 3.44
Quick Ratio 3.26
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

  • MDGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.60%, which is quite impressive.
  • MDGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 864.21%.
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%

3.2 Future

  • Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 36.25% on average per year.
  • The Revenue is expected to grow by 86.51% on average over the next years. This is a very strong growth
EPS Next Y51.27%
EPS Next 2Y43.98%
EPS Next 3Y42.61%
EPS Next 5Y36.25%
Revenue Next Year443.87%
Revenue Next 2Y188.15%
Revenue Next 3Y131.75%
Revenue Next 5Y86.51%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 40 60 80 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • MDGL is valuated quite expensively with a Price/Forward Earnings ratio of 311.66.
  • Based on the Price/Forward Earnings ratio, MDGL is valued cheaply inside the industry as 87.62% of the companies are valued more expensively.
  • MDGL's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.29.
Industry RankSector Rank
PE N/A
Fwd PE 311.66
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDGL does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as MDGL's earnings are expected to grow with 42.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.98%
EPS Next 3Y42.61%

More info and screens

0

5. Dividend

5.1 Amount

  • MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (1/20/2026, 3:16:56 PM)

503.68

+2 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners96.8%
Inst Owner Change0.04%
Ins Owners1.13%
Ins Owner Change1.75%
Market Cap11.44B
Revenue(TTM)740.64M
Net Income(TTM)-289.13M
Analysts83.48
Price Target619.48 (22.99%)
Short Float %17.7%
Short Ratio10.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.41%
Min EPS beat(2)-133.61%
Max EPS beat(2)48.79%
EPS beat(4)3
Avg EPS beat(4)-8.49%
Min EPS beat(4)-133.61%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-2.09%
EPS beat(12)6
Avg EPS beat(12)-1.21%
EPS beat(16)8
Avg EPS beat(16)-1.44%
Revenue beat(2)2
Avg Revenue beat(2)21.21%
Min Revenue beat(2)13.88%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)15.85%
Min Revenue beat(4)2.78%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.09%
PT rev (3m)26.76%
EPS NQ rev (1m)-3.28%
EPS NQ rev (3m)78.57%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-5.26%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)11.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 311.66
P/S 15.44
P/FCF N/A
P/OCF N/A
P/B 18.28
P/tB 18.5
EV/EBITDA N/A
EPS(TTM)-12.89
EYN/A
EPS(NY)1.62
Fwd EY0.32%
FCF(TTM)-7.25
FCFYN/A
OCF(TTM)-7.07
OCFYN/A
SpS32.61
BVpS27.55
TBVpS27.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.25%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.34%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.44
Quick Ratio 3.26
Altman-Z 7.83
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
EPS Next Y51.27%
EPS Next 2Y43.98%
EPS Next 3Y42.61%
EPS Next 5Y36.25%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%
Revenue Next Year443.87%
Revenue Next 2Y188.15%
Revenue Next 3Y131.75%
Revenue Next 5Y86.51%
EBIT growth 1Y43.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.19%
EBIT Next 3Y41.27%
EBIT Next 5YN/A
FCF growth 1Y45.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.97%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


What is the valuation status for MDGL stock?

ChartMill assigns a valuation rating of 2 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


Can you provide the profitability details for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MADRIGAL PHARMACEUTICALS INC?

The Earnings per Share (EPS) of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 51.27% in the next year.